Loading…
Prime Medicine, Inc. is projected to rise to $4.40 by 2027, a +16% move from its current price of $3.78. PRME is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.58 | $3.78 | $3.99 | -0.04% |
| Jul 14 | $3.50 | $3.78 | $4.08 | -0.07% |
| Jul 15 | $3.44 | $3.78 | $4.15 | -0.11% |
| Jul 16 | $3.39 | $3.77 | $4.21 | -0.14% |
| Jul 17 | $3.34 | $3.77 | $4.26 | -0.18% |
| Jul 18 | $3.30 | $3.77 | $4.31 | -0.21% |
| Jul 19 | $3.27 | $3.77 | $4.35 | -0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.27 | $3.77 | $4.35 | -0.25% |
| Week 2 | $3.07 | $3.76 | $4.61 | -0.49% |
| Week 3 | $2.93 | $3.75 | $4.81 | -0.74% |
| Week 4 | $2.81 | $3.74 | $4.99 | -0.98% |
| Week 5 | $2.71 | $3.73 | $5.15 | -1.23% |
| Week 6 | $2.62 | $3.72 | $5.30 | -1.47% |
| Week 7 | $2.54 | $3.72 | $5.43 | -1.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prime Medicine, Inc. is a biotechnology company in the Healthcare sector that focuses on delivering genetic medicines in the United States by deploying gene editing technology. Its lead therapeutic PM359 for Chronic Granulomatous Disease is in Phase 1/2; PM577 for Wilson Disease is in preclinical studies; and PM647 to treat a genetic disorder caused by mutations in the SERPINA1 gene.
The company also pursues in vivo programs targeting diseases of the liver, and Cystic Fibrosis programs, and offers Prime Editing technology comprising programmable DNA binding domains such as Cas domains modified to avoid double-stranded breaks, as well as an RT domain that copies the edited DNA sequence, and pegRNA which provides a target genomic address for the Prime Editor. Prime Medicine has research collaborations and license agreements with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc.
was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Prime Medicine, Inc. sits in the Healthcare sector as a biotechnology company focused on genetic medicines. The stock trades at $3.70 per share with a market capitalization of $667.38M and is ranked 2823.
The thirty‑day price range spans from $2.58 to $5.29, with near-term support at $2.71 and resistance at $4.62. The forecast shows a gradual upside path, with the average price rising across years and culminating in higher levels by 2050.
A major floor 52.6% below — a decisive break under it would weaken the trend.
The nearest floor, 28.3% below — buyers have tended to step in here.
The nearest ceiling, 22.2% above — a clean break opens room to run.
A major ceiling 48.5% above — clearing it would confirm fresh momentum.
Key PRME support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRME market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.12 | Sell | $4.03 | Sell |
| MA 10 | $3.92 | Sell | $3.89 | Sell |
| MA 20 | $3.49 | Buy | $3.66 | Buy |
| MA 50 | $3.30 | Buy | $3.47 | Buy |
| MA 100 | $3.51 | Buy | $3.51 | Buy |
| MA 200 | $3.92 | Sell | $3.60 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.14 | Neutral |
| Stoch RSI (14) | 16.61 | Buy |
| CCI (20) | 44.01 | Neutral |
| Williams %R (14) | -56.00 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 16.67 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 44.00 | Neutral |
| TRIX (15) | 0.80 | Buy |
| Awesome (5,34) | 0.77 | Buy |
| Ultimate (7,14,28) | 54.53 | Neutral |
| Momentum (10) | 0.60 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 4.31 | Sell |
| ADX (14) | 21.46 | Buy |
| ATR (14) | 0.20 | Info |
The 30‑day technical picture shows bullish sentiment with RSI(14) at 50, a 50‑day simple moving average of $3.30 and a 200‑day simple moving average of $3.92. Support is placed at $2.71 and resistance at $4.62, framing a near‑term range of $2.58 to $5.29.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.70 | $3.78 | $4.71 | 0% | Neutral | |
| $3.19 | $4.40 | $6.56 | +16% | Neutral | |
| $3.87 | $5.67 | $9.01 | +50% | Bullish | |
| $4.06 | $6.27 | $10.45 | +66% | Bullish | |
| $3.85 | $6.23 | $10.81 | +65% | Bullish | |
| $3.37 | $5.69 | $10.23 | +51% | Bullish | |
| $3.56 | $6.27 | $11.62 | +66% | Bullish | |
| $3.54 | $6.50 | $12.38 | +72% | Bullish | |
| $4.22 | $8.05 | $15.72 | +113% | Bullish | |
| $5.25 | $10.42 | $20.82 | +176% | Bullish | |
| $5.98 | $13.29 | $29.17 | +252% | Bullish | |
| $7.78 | $17.28 | $39.76 | +357% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.70 | $3.78 | $4.57 | +0.00% |
| August 2026 | $3.17 | $3.84 | $4.85 | +1.63% |
| September 2026 | $2.98 | $3.66 | $4.71 | -4.71% |
| October 2026 | $2.65 | $3.29 | $4.31 | -10.09% |
| November 2026 | $2.64 | $3.31 | $4.40 | +0.65% |
| December 2026 | $2.75 | $3.49 | $4.71 | +5.45% |
Click any year to see its month-by-month PRME forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PRME to range from $2.70 to $4.71 through 2026. The $3.78 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The PRME price prediction for 2027 points to an average of $4.40 (low $3.19, high $6.56) — a potential gain of +16% on today's $3.78. Price action looks broadly range-bound.
In 2028, PRME is projected to trade between $3.87 and $9.01, averaging $5.67 — a potential gain of +50% from today's $3.78. That is up +29% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Prime Medicine, Inc.'s 2029 outlook centres on $6.27, within a $4.06 to $10.45 range. That is up +10% on the projected 2028 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2030, PRME could reach as high as $10.81, with a base case around $6.23 and support toward $3.85 — roughly +65% from $3.78. Buyers look set to stay in control over this stretch.
Expect PRME to range from $3.37 to $10.23 through 2031. The $5.69 average target implies a +51% move from current prices. That is -9% versus the projected 2030 average. Momentum favours further upside here.
The PRME price prediction for 2032 points to an average of $6.27 (low $3.56, high $11.62) — a potential gain of +66% on today's $3.78. Buyers look set to stay in control over this stretch.
In 2033, PRME is projected to trade between $3.54 and $12.38, averaging $6.50 — a potential gain of +72% from today's $3.78. That is up +4% on the projected 2032 average. Momentum favours further upside here.
Prime Medicine, Inc.'s 2034 outlook centres on $8.05, within a $4.22 to $15.72 range. That is up +24% on the projected 2033 average. That marks a +113% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, PRME could reach as high as $20.82, with a base case around $10.42 and support toward $5.25 — roughly +176% from $3.78. Momentum favours further upside here.
Expect PRME to range from $5.98 to $29.17 through 2040. The $13.29 average target implies a +252% move from current prices. That is up +27% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The PRME price prediction for 2050 points to an average of $17.28 (low $7.78, high $39.76) — a potential gain of +357% on today's $3.78. Momentum favours further upside here.
Investing $1,000 in PRME today (≈ 264.550265 PRME) could be worth
$4,572.7
+$3,572.7 (+357%) by 2050 · US Dollar
Based on the average projected PRME price of $17.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRMEwould be worth at today's price.
$1,000 invested in PRME on Jul 10, 2025 (≈ 213.219614 PRME) would be worth
$805.97
-$194.03 (-19.4%) today · 0.81× · US Dollar
Based on a PRME entry price of $4.69 vs. today's $3.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.87 | $976.74 | -2.3% |
| 1 month ago | $2.71 | $1,394.83 | +39.5% |
| 3 months ago | $3.43 | $1,102.04 | +10.2% |
| 6 months ago | $4.28 | $883.18 | -11.7% |
| 1 year ago | $4.69 | $805.97 | -19.4% |
| All time (3.7y) ago | $15.37 | $245.93 | -75.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRME forecast.
Our base-case forecast reaches $7.60 around 2034.
Implied market cap at $7.60: $1.37B
The multi‑year forecast portrays a rising price path with 2026 an average of $3.70 and a min of $2.70 and max of $4.60 (ROI 0, sentiment Neutral). By 2030, the average is $6.08 with a min of $3.76 and a max of $10.56 (ROI 64.6, sentiment Bullish). The forecast continues higher through the mid‑2030s and beyond, with 2034 averaging $7.89 (min $4.13, max $15.41, ROI 113.6, Bullish) and 2035 averaging $10.19 (min $5.13, max $20.36, ROI 175.8, Bullish).
The path extends to 2040 averaging $13.01 (min $5.85, max $28.56, ROI 252.1, Bullish) and to 2050 averaging $16.89 (min $7.60, max $38.84, ROI 357, Bullish). These figures illustrate substantial upside potential over the long term, tempered by the typical uncertainties of biotech outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $6.08 with a min of $3.76 and a max of $10.56, and a predicted ROI of 64.6% with a Bullish sentiment.
The longer‑term forecast shows growing average prices and high max targets with Bullish sentiment in later years (e.g., 2034 max $15.41, 2050 max $38.84) and notable ROIs, but the 2026 year is Neutral and the figures are estimates, not guarantees.
Yes, the forecast shows a max of $20.36 in 2035, and higher maxima in later years such as $28.56 in 2040 and $38.84 in 2050.
The current price is $3.70 per share. The 30‑day range is $2.58 to $5.29.
Market capitalization is $667.38M, and the rank is 2823.
Prime Medicine, Inc. Community Discussion
0Share your Prime Medicine, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.